Authors

Yi Lin, MD, PhD

Latest:

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Jose Maria Mazarico Gallego, MD

Latest:

Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Ignace B. Vergote, MD, PhD

Latest:

Dr. Vergote on the Need to Develop Novel Therapies in Endometrial Cancer

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

John Nakayama, MD

Latest:

Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer

John Nakayama, MD, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.

Alison Schram, MD

Latest:

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Thomas Cluzeau, MD, PhD

Latest:

Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML

Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Allen Mo, MD, PhD

Latest:

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Henry S. Park, MD, MPH

Latest:

Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

Deepu Madduri, MD, Mount Sinai Hospital

Latest:

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center

Latest:

Using Oral Therapies to Advance Care in MBC

Larry Hanover

Latest:

Clinical Trial Diversity Efforts Gain Steam

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.

Andrei Gafita, MD

Latest:

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Anne Chiang, MD, PhD, Yale Cancer Center

Latest:

Treatment After Progression of SCLC: Lurbinectedin

Vivek Subbiah, MD, reviews the safety and efficacy of treatment with lurbinectedin in patients who have platinum-sensitive relapsed small cell lung cancer.

Ryan D. Cassaday, MD, University of Washington/Fred Hutch

Latest:

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Stephen Freedland, MD, Cedars-Sinai Medical Center

Latest:

Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf

Latest:

Unanswered Questions in HER2+ Breast Cancer

Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.

Theresa Boyle, MD, PhD

Latest:

Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Prakash Pandalai, MD

Latest:

Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

Prakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Sunandana Chandra, MD, Northwestern Medicine

Latest:

Advances in the Treatment of Malignant Melanoma

Nathan Bahary, MD, PhD

Latest:

Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated Cholangiocarcinoma

Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.

Sarki A. Abdulkadir, MD, PhD

Latest:

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Anita Johnson, MD, FACS

Latest:

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Krish Patel, MD, Swedish Cancer Institute

Latest:

Novel Therapies for R/R Follicular Lymphoma

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Nicholas J. Short, MD

Latest:

Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL

Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Christian Grohe, MD, Evangelical Lung Cancer Hospital

Latest:

EGFR+ NSCLC: Advice for Community Oncologists

A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.

Amishi Y. Shah, MD, MD Anderson Cancer Center

Latest:

Intermediate/Poor-Risk mRCC: Treatment Selection

Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.

Sophie Paczesny, MD, PhD

Latest:

Steroid-Refractory Acute GVHD

Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.

Maria E. Cabanillas, MD, MD Anderson Cancer Center

Latest:

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

Bradley J. Monk, MD, FACOG, FACS

Latest:

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

Latest:

Improving Survival in Metastatic Urothelial Cancer